-
RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies.
Infrastructure: RegMed XB's Pilot Factory
A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies
read more
-
ReGEN Biomedical and Demcon Announce New Partnership
Demcon and ReGEN Biomedical announce a collaboration, with Demcon becoming a shareholder.
read more
Vlaamse regering investeert 15 miljoen euro in RegMed XB voor regeneratieve therapieën
Brussel/Leuven, 15 januari 2024 – Met een investering van 15 miljoen euro in het Vlaams-Nederlandse samenwerkingsverband RegMed XB, zet de Vlaamse Regering onze regio samen met Nederland op de kaart als centrum voor regeneratieve geneeskunde.
read more
Year in Review: RegMed XB Highlights Magazine
As the year draws to a close, we're glad to share with you a special compilation that encapsulates the essence of the RegMed XB journey in 2023.
read more
-
Moonshots (research excellence)
-
Pilot Factory (infrastructure)
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.
-
RegMed XB's Ecosystem
Health Foundations
The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.
read moreAcademic Partners
RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.
read moreIndustrial Partners
Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.
read moreGovernmental Partners
RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.
read more -
-
-
-
-
-
-